What Is Sapropterin and Its Primary Use?
Sapropterin, sold as Kuvan, mainly targets phenylketonuria (PKU), a genetic disorder caused by mutations in the PAH gene that impair phenylalanine hydroxylase activity. This leads to toxic buildup of phenylalanine (Phe) in the blood, risking brain damage if untreated. Sapropterin acts as a synthetic form of tetrahydrobiopterin (BH4), a cofactor that boosts residual enzyme function in responsive patients, allowing better Phe control beyond diet alone [1].
How Does Sapropterin Work in PKU?
It increases phenylalanine hydroxylase activity by up to 30-50% in BH4-responsive PKU patients, often identified via a loading test. Only about 20-30% of PKU patients respond, typically those with milder mutations like certain PAH variants. Non-responders rely on lifelong low-Phe diets [1][2].
Who Makes Sapropterin and What's Its Approval Status?
BioMarin Pharmaceutical developed and markets Kuvan, approved by the FDA in 2007 for PKU patients aged 4+ (expanded to infants in 2018). It's also approved in Europe for hyperphenylalaninemia due to BH4 deficiency. Endari (another BioMarin drug) targets sickle cell disease, but sapropterin is PKU-specific [1][3].
When Does the Kuvan Patent Expire?
Key U.S. patents for Kuvan expired around 2023-2025, with pediatric exclusivity ending in 2020. Generic or biosimilar entry depends on ongoing litigation; DrugPatentWatch tracks no active Orange Book patents post-2023 for core formulation, opening doors for competition [4].
What Side Effects Do PKU Patients Report?
Common issues include headache (26%), runny nose (20%), sore throat (12%), and nausea. Rare risks: hypersensitivity or Phe rebound if stopped abruptly. Long-term data shows good tolerability in responsive patients [1][2].
How Does It Compare to Standard PKU Treatments?
Unlike low-Phe formula diets (mandatory for all PKU), sapropterin reduces dietary restrictions in responders, improving quality of life. Pegvaliase (Palynziq) is an injectable enzyme substitute for adults unresponsive to BH4. No head-to-head trials exist, but sapropterin costs less upfront (~$100K/year vs. pegvaliase's higher price) [1][3].
[1]: FDA Label for Kuvan (https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021937s015lbl.pdf)
[2]: NIH Genetics Home Reference on PKU (https://medlineplus.gov/genetics/condition/phenylketonuria/)
[3]: BioMarin Product Page (https://www.bmrn.com/kuvan/)
[4]: DrugPatentWatch for Sapropterin (https://www.drugpatentwatch.com/p/tradename/KUVAN)